1172 / 1481
RTOG III trial Bradley Lancet Oncology
2 Y survival 50 %
More relapse after 74 Gy
2 Years locoregional relpase rate
60 Gy 30.7% 74 Gy 38.6%
But 60 % of patients introduced by centre
including less than 4 patients
|
|
1172 / 1481
RTOG III trial Bradley Lancet Oncology
2 Y survival 50 %
More relapse after 74 Gy
2 Years locoregional relpase rate
60 Gy 30.7% 74 Gy 38.6%
But 60 % of patients introduced by centre
including less than 4 patients